Document:

EX-10.9

 

 
 Exhibit 10.9 

April 20, 2017 
 Adrian H.B. Gottschalk 

 

	 	Re:	 Employment Offer Letter 

Dear Adrian: 
 On behalf of Foghorn
Therapeutics, Inc. (the “Company”), I am delighted to offer you employment with the Company. This offer letter (the “Offer Letter”) and the accompanying documents and agreements summarize and set forth important terms about
your employment with the Company. 
 1. Title; Place of Employment and Role. Your position will be Chief Executive
Officer, reporting to the Board of Directors (the “Board”). We anticipate that your employment will start effective May 15, 2017 (the “Start Date”). Your primary place of employment shall be located in the greater
Boston, MA area, initially in Cambridge, MA. In your role you are expected to build and supervise a team to execute against objectives and to develop and manage processes and systems to support these functions. You also will be
expected to perform such other services for the Company, including broader corporate responsibilities, as may be assigned to you from time to time by the Board. You shall also have all powers and duties consistent and customarily associated with the
position of Chief Executive Officer. Effective on your Start Date, you shall also be elected as a member of the Board, and you agree to tender your resignation from the Board, if requested by the Board, effective as of the date that you no longer
serve as Chief Executive Officer of the Company or such later date as the Board may request. The Company expects you to devote your full working time and best efforts to the Company. The Company agrees that, subject to notice by you to the Board and
approval from the Board you may serve on the boards of directors of companies or organizations or engage in religious, charitable and other community activities which do not present any conflict of interest with the Company or unreasonably interfere
with your duties and responsibilities hereunder. You will be employed on an at-will basis, which means that neither you nor the Company are guaranteeing this employment relationship for any specific period of
time, subject to the provisions of this Offer Letter. 
 2. Compensation. 

a. Salary. Your initial base pay will be at a rate of $400,000.00 on an annualized basis, minus required deductions for federal
and state taxes and other applicable withholdings in accordance with the Company’s normal payroll practices. 
 b. Signing
Bonus. On or before your Start Date, you shall receive a signing bonus in the amount of $70,000, less required deductions for federal and state taxes and other applicable withholdings. If, prior to the
one-year anniversary of your Start Date, you voluntary terminate your employment not following a “Good Reason Event” (as defined below) or your employment is terminated by the Company for
“Cause” (as defined below) such bonus is subject to repayment, pro-rated based on the number of days employed as of the Termination Date. 

 b. Annual Performance Bonus. You will be eligible to receive an annual bonus
(the “Annual Bonus”) of up to thirty five percent (35%) of your base salary, payable upon the achievement, as determined by the Board, of specific milestones to be mutually agreed in writing. The Annual Bonus will be paid to you no later
than March 15th of the calendar year immediately following the calendar year in which it was earned. You must be employed by the Company as of December 31 of the calendar year to which the
Annual Bonus relates in in order to be eligible for and have earned the Annual Bonus. Your annual bonus for 2017 will be prorated based on the number of days you were employed by the Company in 2017. 

c. Stock Options. 
 (i)
Initial Option Grant: Subject to the terms of and contingent upon your execution of the attached stock option agreement (the “Option Agreement”) issued pursuant to the Company’s 2016 Stock Incentive Plan (the “Plan”),
when established, you will be granted an option to purchase 1,675,000 shares of common stock of the Company at an exercise price equal to the fair market value of the stock on the date of the grant as determined by the Board (“Initial Option
Grant”). This option will vest 25% on the first anniversary of the grant date and the remaining 75% will vest on a quarterly basis on the last day of each quarter over a period of three years following such anniversary, provided that you remain
employed on the vesting date. As stated above, the above-referenced equity grant will be subject to the terms and conditions of the Plan and any Option Agreement executed pursuant thereto. 

d. Benefits. You will be eligible to participate in the Company’s benefit plans to the same extent as, and subject to the
same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure. Summaries of each of the Company’s benefit plans are available to you. Each calendar year you will be eligible to receive four
(4) weeks’ vacation, five (5) days’ sick leave and holidays as set forth by the Company and subject to the Company’s vacation and holiday policies as in effect from time to time. If any benefit is subject to a benefit plan,
the terms of that plan will control. The descriptions of benefits and other compensation arrangements set forth herein are summary in form, and may be subject to change. 

e. Expense Reimbursement. You will be reimbursed for all reasonable out-of-pocket expenses incurred during the performance of your duties, in accordance with the Company’s reimbursement policies as established or modified from time to time by the Company. Any
reimbursements or direct payment of expenses subject to Section 409A (“Section 409A”) of the Internal Revenue Code (the “Code”) will be for expenses incurred during your lifetime (or during a shorter period of time
specified in this Offer Letter), and will be made no later than the end of the calendar year following the calendar year in which such expense is incurred by you. Any reimbursement or right to direct payment of your expense in one calendar year will
not affect the amount that may be reimbursed or paid for in any other calendar year, and any reimbursement or payment of your expense (or right thereto) may not be exchanged or liquidated for another benefit or payment. 

f. Investment in Company Preferred Stock. The Company acknowledges that you have indicated an interest in making an investment
in the Company in connection with the closing of the Second Tranche, as defined in the Series A-1 and A-2 Preferred Stock Purchase Agreement dated as of April 11,
2016 among the Company and the Purchasers named therein (the “Purchase Agreement”), regarding the issuance by the Company of shares of Series A-2 Preferred Stock of the Company. The Company is
willing to permit you to participate in such Second Tranche. In connection with investing in such Second Tranche, you shall become a party to the Purchase Agreement and all other Transaction Agreements, as defined in the Purchase Agreement. 

  
 2 

 3. Severance Pay and Benefits. As stated above, the parties’ employment
relationship is at-will, and may be terminated at any time and for any reason. In the event of a separation of employment, the Company will provide you with all amounts required to be paid under law and
policy, including earned wages, accrued but unused vacation, and incurred but unreimbursed expenses. In addition, you may be eligible for additional severance payments and benefits under certain circumstances, as described below. 

a. Termination Other Than for Cause or Resignation following a Good Reason Event. Should the Company terminate your employment
other than for Cause or should you resign your employment following a Good Reason Event or then, conditioned upon your execution and non-revocation of a full and general release of claims to the Company and
its affiliates and their respective directors, officers, agents and employees (in the form attached as Exhibit A) and compliance with your Confidentiality Agreement described in Section 6 below: (i) the Company will provide you
with severance payments equal to twelve (12) months of your then current base salary, less applicable withholdings and deductions, payable in periodic installments over 6 months in accordance with the Company’s normal payroll practices;
(ii) if a premium subsidy is not illegal or discriminatory under applicable law, and if you properly elect to receive benefits under the Consolidated Omnibus Budget Reconciliation Act (“COBRA”), then the Company will provide you with
12 months of your COBRA premiums at the Company’s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination; (iii) all stock options or stock awards held by you that would have
vested in the twelve (12) month period following the date of termination based solely on the passage of time shall, as of the date of such termination, immediately accelerate and become exercisable with respect to such additional shares
that would have vested in such 12-month period. 
 b. Termination Other Than for Cause or
Resignation following a Good Reason Event Within Twelve (12) Months following a Change of Control. Should the Company terminate your employment other than for Cause or should you resign following a Good Reason Event during the
period beginning four (4) months prior to and ending twelve (12) months following the consummation of a Change of Control (defined below) then, also conditioned upon your execution and non-revocation
of Exhibit A and compliance with your Confidentiality Agreement: (i) the Company will provide you with severance payments equal to twelve (12) months of your then current base salary less applicable withholdings and deductions,
payable in periodic installments over twelve (12) months in accordance with the Company’s normal payroll practices; (ii) if a premium subsidy is not illegal or discriminatory under applicable law, and if you properly elect to receive
benefits under COBRA, then the Company will provide you with 12months of your COBRA premiums at the Company’s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination; and
(iii) all stock options with time-based vesting or other stock-based awards with time-based vesting held by you as of the date of termination will immediately accelerate and become fully exercisable or
non-forfeitable as of date of termination. Please note that if you are entitled to the payments and benefits described in this Section 3.b., then you will not be entitled to the payments and benefits
described in Section 3.a. above. 
 c. Timing. Any severance payments paid under this Section 3 will commence within
60 days after the date of termination; provided that if the 60-day period begins in one calendar year and ends in a second calendar year, then the severance payments will commence in the second calendar year
by the last day of such 60-day period, and further provided that the initial severance payment will include a catch-up payment to cover amounts retroactive to the day
immediately following the date of termination. 

  
 3 

 d. Definitions. 

(i) “Change of Control” means: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the
Exchange Act) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power
represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series
of related transactions other than a bona fide financing; or (ii) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company
outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power
represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (iii) the sale or disposition by the Company of all
or substantially all of the Company’s assets in a transaction or series of related transactions. “Change of Control” will be interpreted, if applicable, in a manner, and limited to the extent necessary, so that it will not cause
adverse tax consequences under Section 409A of the Code. 
 (ii) “Cause” means any one or more of the following
actions: (i) your material breach of the terms of this Offer Letter or your Confidentiality Agreement which is not cured within thirty (30) days of your written notice specifying in reasonable detail the facts and circumstances regarding
the alleged breach; (ii) your grossly negligent, malfeasant, dishonest or reckless conduct in the performance of your duties that causes material harm to the Company; (iii) your commission of an act of fraud, theft, misappropriation or
embezzlement in the performance of your duties; or (iv) your conviction, or pleading nolo contendere, to a felony or any crime involving moral turpitude. 

(iii) “Good Reason Event” means the occurrence of any of the following actions undertaken by the Company without your express
prior written consent, provided that you have complied with the “Good Reason Process” (hereinafter defined) following same: (i) a material diminution in your, responsibilities, authority or function; or (ii) a reduction in your
base salary (other than reductions in salaries generally for employees of executives of the Company; or (iii) a requirement by the Company that you relocate your principal location of employment to a location that is more than forty
(40) miles from your primary work location; (iii) a material breach by the Company of this Offer Letter or the Option Agreement or any other agreements referenced herein; .. “Good Reason Process” means that (1) you have
reasonably determined in good faith that a Good Reason Event has occurred; (2) you have notified the Company in writing of the first occurrence of the Good Reason condition within ninety (90) days of the first occurrence of such condition;
(3) the Company has failed to cure the Good Reason Event within thirty (30) days following such notice (the “Cure Period”), provided that you have cooperated in good faith with the Company’s efforts to remedy the condition;
(4) you terminate your employment within thirty (30) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason will be deemed not to have occurred. 

4. Confidentiality and Other Obligations. As part of your employment with the Company, you will be exposed to and provided with
valuable confidential and trade secret information concerning the Company. As a result, in order to protect the Company’s legitimate business interests, you agree, as a condition of your employment, to enter into the enclosed Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement (the “Confidentiality Agreement”). You must sign and return the
Confidentiality Agreement before beginning your employment with the Company. 
 5. Certifications by You. By signing this
Offer Letter, you are certifying to the Company that: (a) your employment with the Company does not, and will not, require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any
agreements 

  
 4 

 
with previous employers that are in conflict with your obligations to the Company); and (b) to the extent you are subject to restrictive agreements with any prior employer that may affect
your employment with the Company, you have provided the Company with a copy of that agreement. Please understand that the Company does not want you to disclose any confidential information belonging to a previous employer or to incorporate the
proprietary information of any previous employer into the Company’s proprietary information and expects that you will abide by restrictive covenants to prior employers. 

6. Required I-9 Documentation. For purposes of completing the INS I-9 form, you must provide us sufficient documentation to demonstrate your eligibility to work in the United States on or before your first day of employment. Your employment with the Company is conditioned on your
eligibility to work in the United States. 
 7, No Duty to Mitigate. The Executive shall not be required to mitigate the amount of
any payment contemplated by this Agreement, nor shall any such payment be reduced by any earnings that the Executive may receive from any other source. 

8. Section 409A and 280G. 

a. The parties intend this Offer Letter and the payments required hereunder to be either in compliance with or exempt from
Section 409A of the Code. It is intended that each installment of the payments and benefits provided under this Offer Letter will be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the Company
nor you will have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code. 

b. Notwithstanding any other provision of this Offer Letter to the contrary, if any amount to be paid to you pursuant to this Offer
Letter as a result of your termination of employment is “deferred compensation” subject to Section 409A of the Code, then: (i) if you are a “Specified Employee” (as defined under Section 409A of the Code) as of the date
of your termination of employment, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Section 409A of the Code, the payment of benefits, if any, scheduled to be paid by the Company to you hereunder
during the first 6-month period following the date of a termination of employment hereunder will not be paid until the date which is the first business day after 6 months have elapsed since your termination of
employment for any reason other than death; any deferred compensation payments delayed in accordance with the terms of this section will be paid in a lump sum after 6-months have elapsed since your termination
of employment; any other payments will be made according to the schedule provided for herein; and (ii) any termination of employment triggering payment of such benefits must constitute a “separation from service” under
Section 409A of the Code before distribution of such benefits can commence; to the extent that the termination of your employment does not constitute a “separation from service” under Section 409A of the Code (as the result of
further services that are reasonably anticipated to be provided by you to the Company at the time your employment terminates), any benefits payable under this Offer Letter that constitute “deferred compensation” under Section 409A of
the Code will be delayed until after the date of a subsequent event constituting a “separation from service” under Section 409A of the Code. For purposes of clarification, this section will not cause any forfeiture of benefits on your
part, but will only act as a delay until such time as a “separation from service” occurs. 
 c. If any payment or benefit
you would receive from the Company, when combined with any other payment or benefit you receive or are entitled to receive from the Company (for purposes of this section, a “Payment”) would: (i) constitute a “parachute
payment” within the meaning of Section 280G the Code; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code 

  
 5 

 
(the “Excise Tax”), then such Payment will be either: (A) the full amount of such Payment; or (B) such lesser amount (with cash payments being reduced before stock option
compensation) as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes, and the Excise Tax, results
in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. 

9. Indemnification. The Company shall indemnify and hold you harmless for any liability, including reasonable attorneys’
fees and costs, incurred by reason of any act or omission by you in your capacity as an employee, director, and/or officer of the Company to the extent permitted by the Company’s certificate of incorporation, as amended. 

10. General. This Offer Letter, together with the Confidentiality Agreement and the Option Agreement and any other agreements
specifically referred to herein, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject
matter hereof. The terms this Offer Letter may be modified only by written agreement executed by the parties hereto, and may be waived (or consent for the departure there from granted) only by a written document executed by the party entitled to the
benefits of such terms. Because our employment discussions and the terms of your employment are confidential, it is understood that you will not disclose the terms of such discussions or the terms of your employment with the Company to anyone other
than your immediate family and your legal or financial advisor at any time, absent prior written consent from the Company. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all
of the Company’s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company will be void. This
Offer Letter will be construed in accordance with and governed by the law of Massachusetts, without giving effect to the conflict of law principles thereof. By accepting this offer of employment, you agree that any action, demand, claim or
counterclaim in connection with any aspect of your employment with the Company, or any separation of employment will be brought in the courts of the Commonwealth of Massachusetts or of the United States of America for the District of Massachusetts.

 [Signature Page Follows] 

  
 6 

 Please acknowledge acceptance of this Offer Letter by signing and dating below. Keep one
copy for your files and return one executed copy to me. Adrian, we look forward to having you on the team. 
  

			
	Very truly yours,
	
	Foghorn Therapeutics, Inc.
		
	By:	 	     /s/ Douglas Cole      

	Douglas Cole
	President

  

	
	Accepted and Agreed:
	
	 /s/ Adrian H.B. Gottschalk

	Adrian H.B. Gottschalk
	
	 4/20/2017

	Date

  
 7 

 Exhibit A 

Form of Release 
 [To be
inserted] 

  
 8EX-10.10

 Exhibit 10.10 

July 11th, 2019 

Sam Agresta, M.D. 
 Dear Sam, 

On behalf of Foghorn Therapeutics (the “Company”), I am delighted to offer you employment with the Company. This offer letter (the “Offer
Letter”) and the accompanying documents and agreements summarize and set forth important terms about your employment with the Company. 
 1.
Starting Date, Position, and Duties. 
 a. Your initial position shall be Chief Medical Officer. In your role, you shall
report to the Chief Executive Officer of the Company (the “CEO”). We anticipate that your employment shall start on or before September 9th, 2019 (the “Start Date”). In this
key position you shall have responsibility for leading and managing the clinical development, clinical operations, and regulatory-related interactions of the Company’s drug programs. In your role, you are expected to build and supervise a team
in coordination with the CEO to execute against objectives and to develop and manage processes and systems to support these functions. It is understood that you will be employed by the Company in such capacity or such other capacity as may be
mutually agreed upon by the Company and you from time to time. As a member of our team, we expect you to devote all of your professional and working time and energies to the business and affairs of the Company. You shall not engage in non-Company related business activities (including consulting activities, board memberships and academic appointments) without Company’s prior written consent, which Company may withhold in its sole discretion.
Provided that you receive the Company’s consent to do so, your conduct of any such non-Company related business activities shall not interfere with the performance of your duties hereunder and shall not
violate the provisions of your Confidentiality Agreement (as described below). For the avoidance of doubt, Company does consent to you providing limited consulting services to your most-recent employer (“Former Employer”) until
November 30, 2019 provided that such consulting services: (i) do not interfere with the performance of your duties hereunder; and (ii) do not violate the provisions of your Confidentiality Agreement. 

b. As is generally true for Company employees, you shall be employed on an at- will basis,
which means that neither you nor the Company are guaranteeing this employment relationship for any specific period of time. Either of us may choose to end the employment relationship at any time, for any reason, with or without notice. If any
benefit is subject to a benefit plan, the terms of that plan shall control. Other than the terms of this Offer Letter, the Company reserves the right to alter, supplement or rescind its employment procedures, benefits or policies (other than the
employment at-will policy) at any time in its sole and absolute discretion and without notice. 

 2. Compensation. During your employment hereunder, as compensation for all services performed
for the Company and its affiliates, the Company will provide you with the following compensation and benefits: 
 a. Salary.
Your initial base pay shall be at a rate of $400,000 on an annualized basis, less required deductions for federal and state taxes and other applicable withholdings, and payable in accordance with the Company’s normal payroll practices. 

b. Signing Bonus. In the first company pay cycle following your Start Date, you shall receive a
one-time signing bonus (“Signing Bonus”) in the amount of $75,000, less required deductions for federal and state taxes and other applicable withholdings. If, prior to the one-year anniversary of your Start Date, you voluntary terminate your employment and such voluntary termination does not qualify as a “Resignation for Good Reason” (as defined below) or your employment is
terminated by the Company for “Cause” (as defined below) such Signing Bonus shall be repaid in full within thirty (30) days following the date your employment terminates. 

c. Transition Payment. In the first company pay cycle following your Start Date, you shall receive a one-time additional payment (the “Transition Payment”) in the amount of $65,000, less required deductions for federal and state taxes and other applicable withholdings. If, prior to the two-year anniversary of your Start Date, you voluntary terminate your employment and such voluntary termination does not qualify as a “Resignation for Good Reason” (as defined below) or your employment is
terminated by the Company for “Cause” (as defined below) such Transition Payment shall be repaid in full within thirty (30) days following the date your employment terminates. 

d. Annual Performance Bonus and Up-Front Option. In accordance with the Company’s
Bonus Plan, you shall be eligible to receive an annual bonus of up to 40% of your base salary, payable upon the achievement, as determined by the Board of Directors of the Company (the “Board”) in its sole discretion, of specific
milestones to be mutually agreed in writing. The annual bonus shall be paid to you no later than March 15th of the calendar year immediately following the calendar year in which it was earned. Except as expressly provided below, you must be employed
by the Company or on an approved leave of absence on the date of payment of the bonus in order to be eligible for and have earned the annual bonus. 

You have indicated that you may be contractually responsible for repaying your prior employer a
sign-on bonus. Should you be required to repay the sign-on bonus to your prior employer, you shall notify the Company within ten (10) days of the date that your
prior employer notifies you of such requirement to repay. In the next Company pay cycle following the date you so notify the Company, the Company shall pay you an amount not greater than $160,000 (the
“Up-Front Payment”), less required deductions for federal and state taxes and other applicable withholdings, as a one-time payment. To the extent paid, the
amount of any annual bonus that you would otherwise be eligible to earn for 2019 and 2020 shall be reduced by the Up-Front Payment, with the 2019 annual bonus reduced first (but not below zero) and any
remaining reduction taken from the 2020 annual bonus. For the avoidance of doubt, the entirety of such Up-Front Payment must be used to repay your prior employer. If, prior to the two-year anniversary of your Start Date, you voluntary terminate your employment and such voluntary termination does not qualify as a “Resignation for Good Reason” (as defined below) or your employment is
terminated by the Company for “Cause” (as defined below), you will be obligated to pay an amount equal to the Up-Front Payment less any amount that was awarded to you as a bonus payment within thirty
(30) days following the date your employment terminates. 

  
 - 2 - 

 e. Equity Grants. Subject to the terms and conditions of this
Section 2.e. and any applicable policies and agreements (including but not limited to the “Equity Plan” and “Equity Agreements” described below), you shall be eligible for the following grant: 

 

	 	i.	 Option Grant. Provided you commence employment with the Company on or before September 9th, 2019, subject to the approval of the Board, you will be granted an option to purchase 575,900 shares of common stock of the company at an exercise price equal to the fair market value of the stock
on the date of the grant as determined by the Board. This stock option shall vest 25% on the first anniversary of the grant date, and the remaining 75% of the stock option shall vest on a quarterly basis on the first day of each calendar quarter for
the 12 quarters thereafter, subject to your continued employment with the Company. 

  

	 	ii.	 Terms and Conditions. In all respects, the stock option described in this Section 2 shall be
governed by the 2016 Equity Incentive Plan (the “Equity Plan”) and an applicable Stock Option Agreement (as applicable, an “Equity Agreement”) executed by you pursuant thereto. The stock option described in this Section 2
shall be, to the maximum extent permissible, treated as “incentive stock options” within the meaning of Section 422 of the Internal Revenue Code and the rules and regulations thereunder. 

 

	 	iii.	 Accelerated Vesting. If you are subject to an Involuntary Termination (as defined below) outside of a
CIC Period (as defined below), then the vesting and, if applicable, the exercisability of each of your outstanding equity-based awards under the Equity Plan or any other equity-based plan maintained by the Company or any applicable successor plans
thereto shall be partially accelerated such that the number of shares subject to each such equity-based award that would have vested during the 12-month period following your Separation (as defined below) (or,
in the case of an equity-based award in which vesting of the shares is subject to the achievement of a performance-based condition, then 25% of the shares subject to such equity-based award (at target)) shall remain outstanding and eligible to vest
and be vested and, if applicable, exercisable as of the effective date of the Release (as defined below). In addition, if you are subject to an Involuntary Termination during the CIC Period, then all of your then-unvested equity-based awards under
the Equity Plan shall remain outstanding and be fully accelerated and, if applicable, exercisable as of the effective date of the Release. 

f. Benefits. You shall be eligible to participate in the Company’s benefit plans to the same extent as, and subject to the
same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure. Summaries of each of the Company’s benefit 

  
 - 3 - 

 
plans are available to you. These benefits may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits does not change your
status as an at-will employee. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is
governed solely by the applicable plan document. 
 g. Expense Reimbursement. The Company shall reimburse you for all ordinary
and reasonable out-of-pocket business expenses incurred in furtherance of the Company’s business in accordance with the Company’s policies with respect thereto
as in effect from time to time. You must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred. All reimbursements hereunder shall be made or provided in accordance with
the requirements of Section 409A (“Section 409A”) of the Internal Revenue Code and the rules and regulations thereunder (the “Code”) including, where applicable, the requirement that: (i) any reimbursement is for
expenses incurred during your lifetime (or during a shorter period of time specified in this Offer Letter); (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any
other calendar year; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred; and (iv) the right to reimbursement or in kind benefits
is not subject to liquidation or exchange for another benefit. 
 3. Severance Benefit upon Termination without Cause Following Change of Control.

 a. Notwithstanding the at-will nature of the parties’ relationship, should you be
subject to an Involuntary Termination, then conditioned upon your timely execution and non-revocation of a separation agreement containing a release of claims and other customary terms in the form provided by
the Company (the “Release”) and compliance with your Confidentiality Agreement described below then: (i) the Company shall provide you with a payment in an amount equal to 9 months of your then current base salary payable in the form
of salary continuation over the 9-month period following the date of separation, commencing on the first regular Company payday that is at least 5 business days following the effective date of the Release;
(ii) (x) if the Company is subject to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) or similar state law, (y) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient
Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, and (z) if you properly elect to receive benefits under COBRA, then the Company shall provide you with 9 months of your COBRA premiums at the Company’s
normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis; (iii) the Company shall pay the amount of any annual bonus previously
awarded to you by the Board with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of
the Company; and (iv) subject to the terms and conditions of the Equity Plan and Equity Agreements, any portion of any stock option granted to you that remains outstanding as of the date of separation and that has vested as of such date (or
that vests in accordance with the provisions of Section 2(d)(iii)) shall remain outstanding and exercisable for a period of 3 months following the Separation Date or, if earlier, the normal 10-year
expiration date of such stock options. 

  
 - 4 - 

 b. For purposes of this offer letter, “Cause” means any one or more
of the following actions: (i) your material breach of the terms of this Offer Letter or your breach of the terms of the Confidentiality Agreement; (ii) your material dishonesty, willful misconduct, gross negligence, or reckless conduct, in
each case if such conduct is in connection with the performance of your services to the Company or any of its affiliates; (iii) your commission of an act of fraud, theft, misappropriation or embezzlement that is, in each case, materially
injurious to the Company or any of its affiliates; (iv) your indictment of, or pleading nolo contendere to, any crime involving moral turpitude or any felony; or (v) your material violation of a Company policy that had been previously
provided to you in writing or your willful refusal to perform, or substantial negligence in the performance of, your assigned duties to the Company or any of its affiliates (other than as a result of your mental or physical impairment). For purpose
of clauses (i), (ii), (iii), and (v), “Cause” will only exist if: (1) the Company delivered to you a written description of the events or conditions giving rise to your termination for Cause; and (2) if curable, you have been
given at least 15 days to cure such events or conditions and you fail to cure such events or conditions within such time period given. 

c. For purposes of this offer letter, “Change of Control” means: (i) any “Person” (as such term is used in
Sections 13(d) and 14(d) of the Exchange Act) that becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing
50% or more of the total voting power represented by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company)
pursuant to a transaction or a series of related transactions which the Board does not approve; or (ii) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in
the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50%
of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (iii) the sale or
disposition by the Company of all or substantially all of the Company’s assets in a transaction requiring stockholder approval; notwithstanding the foregoing, no transaction or series of transactions shall constitute a Change of Control unless
such transaction or series of transactions constitutes a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i). 

d. For purposes of this offer letter, “CIC Period” means the period commencing on the date that is three months prior
to the date on which a Change of Control occurs and ending on the date that is 12 months following such occurrence. 
 e. For
purposes of this offer letter, “Involuntary Termination” means either (a) your Termination Without Cause or (b) your Resignation for Good Reason. 

  
 - 5 - 

 f. For purposes of this offer letter, “Resignation for Good Reason”
means a Separation as a result of your resignation within 180 days after one of the following conditions has come into existence without your consent: 
  

	 	i.	 A reduction in your base salary other than in connection with an across-the-board reduction affecting all similarly situated executives of the Company; 

  

	 	ii.	 A material diminution of your title, authority, duties or responsibilities; 

 

	 	iii.	 A material breach of this agreement by Company; or 

 

	 	iv.	 A relocation of your principal workplace by more than 50 miles. 

A Resignation for Good Reason will not be deemed to have occurred unless you give the Company written notice of the condition within 90 days after the
condition comes into existence and the Company fails to remedy the condition within 30 days after receiving your written notice. 

g. For purposes of this offer letter, “Separation” means a “separation from service,” as defined in the
regulations under Section 409A of the Code. 
 h. For purposes of this offer letter “Termination Without Cause”
means a Separation as a result of a termination of your employment by the Company without Cause (and not as a result of your death or disability), provided you are willing and able to continue performing services within the meaning of Treasury
Regulation 1.409A-1(n)(1). 
 i. Any severance payments paid under this Section 3 shall
commence within 60 days after the date of termination (or at such earlier time as provided in this Section 3); provided, however, that if the 60-day period begins in one calendar year and ends in a second
calendar year, the severance payments begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the date of termination. Each payment pursuant to this Offer Letter is intended to constitute a separate payment for purposes of
Treasury Regulation Section 1.409A-2(b)(2). 
 j. Should you voluntarily terminate your
employment for any reason (other than for Good Reason) or should your employment be terminated for Cause (whether before or after a Change of Control) or as a result of your death or disability, then you shall not be entitled to any severance
payments described herein. Nothing in this Section 3 shall alter your status as an at-will employee. 

k. Vesting in the Event of a Change of Control or Death. Notwithstanding anything to the contrary hereunder or in the Equity
Plan or an applicable Equity Agreement, in the event of a Change of Control, subject to your continued employment through such Change of Control, or your death, then you (or your estate, as applicable) automatically shall vest in all of the
then-unvested shares subject to the equity awards under the Plan as of the date of the consummation of such Change of Control or the date of death, as applicable. 

4. Certification. By signing this Offer Letter, you are certifying to the Company that: (a) your employment with the Company does not and
shall not require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any agreements with previous employers that are in conflict with your obligations to the Company); (b) to the
extent you are subject to restrictive agreements with any prior employer that may affect 

  
 - 6 - 

 
your employment with the Company, you have provided us with a copy of that agreement; (c) your employment with the Company does not violate any order, judgment or injunction applicable to
you, and you have provided the Company with a copy of any such order, judgment, or injunction; and (d) all facts you have presented to the Company are accurate and true, including all statements made to the Company pertaining to your education,
training, qualifications, licensing and prior work experience on any job application, resume or c.v., or in any interview. Please understand that the Company does not want you to disclose any confidential information belonging to a previous employer
or to incorporate the proprietary information of any previous employer into the Company’s proprietary information and expects that you shall abide by restrictive covenants to prior employers. 

5. Required I-9 Documentation. Your employment with the Company is conditioned on your eligibility to
work in the United States. For purposes of completing the USCIS I-9 form, you must provide us with sufficient documentation to demonstrate your identity and eligibility to work in the United States on or
before your first day of employment. 
 6. Confidentiality and Other Obligations. As part of your employment with the Company, you shall be
exposed to, and provided with, valuable confidential and trade secret information concerning the Company and its present and prospective clients. As a result, in order to protect the Company’s legitimate business interests, you agree, as a
condition of your employment, to enter into the enclosed Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement (the
“Confidentiality Agreement”). You must sign and return the Confidentiality Agreement before beginning your employment with the Company. 
 7.
Section 409A and 280G of the Code. 
 a. Notwithstanding any other provision of this Offer Letter to the contrary, if any amount
(including imputed income) to be paid to you pursuant to this Offer Letter as a result of your termination of employment is “deferred compensation” subject to Section 409A of the Code, and if you are a “Specified Employee”
(as defined under Section 409A of the Code) as of the date of your termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Section 409A of the Code, the payment of
benefits, if any, scheduled to be paid by the Company to you hereunder during the first 6-month period following the date of a termination of employment hereunder shall not be paid until the date which is the
first business day after six (6) months have elapsed since your termination of employment for any reason other than death. Any deferred compensation payments delayed in accordance with the terms of this Section 6.a. shall be paid in a lump
sum after 6-months have elapsed since your termination of employment. Any other payments shall be made according to the schedule provided for herein. 

b. If any of the benefits set forth in this Offer Letter are “deferred compensation” under Section 409A of the Code, any
termination of employment triggering payment of such benefits must constitute a “separation from service” under Section 409A of the Code before distribution of such benefits can commence. To the extent that the termination of your
employment does not constitute a “separation from service” under Section 409A of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment terminates),
any benefits payable under this Offer Letter that constitute “deferred 

  
 - 7 - 

 
compensation” under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a “separation from service” under Section 409A of
the Code. For purposes of clarification, this Section 6.b. shall not cause any forfeiture of benefits on your part but shall only act as a delay until such time as a “separation from service” occurs. 

c. It is intended that each installment of the payments and benefits provided under this Offer Letter shall be treated as a separate
“payment” for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by
Section 409A of the Code. 
 d. This Offer Letter shall be interpreted and at all times administered in a manner that avoids the
inclusion of compensation in income under Section 409A of the Code. Any provision inconsistent with Section 409A of the Code shall be read out of this Offer Letter. For purposes of clarification, this Section 6.d. shall be a rule of
construction and interpretation and nothing in this Section 6.d. shall cause a forfeiture of benefits on the part of you. You acknowledge and agree that the Company does not guarantee the tax treatment or tax consequences associated with any
payment or benefit arising under this Offer Letter, including but not limited to consequences related to Section 409A of the Code. 

e. If any payment or benefit you would receive under this Offer Letter, when combined with any other payment or benefit you receive
pursuant to a Change of Control (for purposes of this section, a “Payment”) would: (i) constitute a “parachute payment” within the meaning of Section 280G the Code; and (ii) but for this sentence, be subject to the
excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either: (A) the full amount of such Payment; or (B) such lesser amount as would result in no portion of the Payment being subject
to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax
basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. With respect to subsection (B), if there is more than one method of reducing the payment as would result in no
portion of the Payment being subject to the Excise Tax, then you shall determine which method shall be followed, provided that if you fail to make such determination within five (5) days after Company has sent you written notice of the need for
such reduction, Company may determine the amount of such reduction in its sole discretion. 
 8. General. This Offer Letter, together with the
Confidentiality Agreement and the restricted stock and option agreements and any other agreements specifically referred to herein, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof,
and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. The terms and provisions of this Offer Letter may be modified or amended only by written agreement executed by the parties hereto, and may
be waived (or consent for the departure therefrom granted) only by a written document executed by the party entitled to the benefits of such terms or provisions. The Company may assign its rights and obligations hereunder to any person or entity
that succeeds to all or substantially all of the Company’s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written

  
 - 8 - 

 
consent of the Company shall be void. This Offer Letter and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal law of
Massachusetts, without giving effect to the conflict of law principles of any jurisdiction. By accepting this offer of employment, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the
Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be brought in the courts of Massachusetts or of the United States of America for the District of Massachusetts, and shall be resolved by a judge
alone, and you waive and forever renounce your right to a trial before a civil jury. 
 9. Indemnification. The Company shall indemnify and
hold you harmless for any liability, including reasonable attorneys’ fees and costs, incurred by reason of any act or omission by you in your capacity as an employee and/or officer of the Company to the extent permitted by the Company’s
certificate of incorporation, as amended. 
 This offer shall remain open, unless sooner revoked by the Company, through July 17th, 2019. Please acknowledge acceptance of this employment offer by signing and dating below. Keep one copy for your files and return one executed copy to me. 

We greatly look forward to having you on the team. 
  

			
	Very truly yours,
	
	Foghorn Therapeutics
		
	By:	 	/s/ Adrian Gottschalk
		 	Adrian Gottschalk, President & CEO

  

	
	Accepted and Agreed to:
	
	/s/ Sam Agresta, M.D.
	Sam Agresta, M.D.
	
	July 11, 2019
	Date

  
 - 9 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00314-of-00352.parquet"}]]